On October 14, the US Food and Drug Administration announced its Rare Disease Framework Initiative, a broad effort to reconsider how the agency approaches rare disease drug development and review. The initiative, led by FDA’s Rare Disease Innovation Hub and building on its 2026 Strategic Agenda, seeks to align regulatory expectations with disease-specific circumstances, patient needs, and the evidence that can realistically be generated in small populations.
While the announcement of the Rare Disease Framework Initiative (Framework Initiative) does not yet herald regulatory change, for sponsors and stakeholders, the initiative presents an opportunity to influence future policy and signals the US Food and Drug Administration’s (FDA’s) ongoing focus on managing the challenges that rare disease programs bring to FDA decision-making.
FDA’s Guiding Principles
Alongside the initiative, FDA published an accompanying white paper, A New Framework for Rare Disease Review, which sets out six guiding principles:
- Clarity, consistency, and predictability: Tailored guidance and transparent communication grounded in current science.
- Patient voice: Early integration of patient perspectives on disease burden, benefit-risk priorities, and meaningful measures of progress, incorporated at defined milestones.
- External expertise: Disease experts used as a structural feature of review, especially in small populations where natural history is poorly understood.
- Shared knowledge: Common resources, training, and institutional expertise to promote consistent development and review.
- Risk-based review: Chemistry, manufacturing, and controls (CMC) review and preapproval inspections that support earlier access while preserving quality, safety, and effectiveness.
- Innovative science: Support for novel methods, clinical trial designs, and statistical approaches.
While some of these principles, including those aimed at coordinated and predictable reviews and advancement of innovative regulatory science, revisit FDA’s existing goals (whether in the rare disease space or more broadly), others could eventually lead to regulatory change.
FDA’s focus on earlier input from patients may provide more meaningful opportunities for these perspectives to inform and influence foundational aspects of data packages for rare disease programs. In addition, FDA is more openly acknowledging the challenges created by one-size-fits-all quality, manufacturing, and inspectional standards in the rare disease space.
Expected Outcomes and Deliverables
The white paper identifies four potential deliverables, while emphasizing that stakeholder input will shape the ultimate outcomes:
- Regulatory revisions: Amended or new regulatory provisions could incorporate fit-for-purpose evidentiary standards into the legal foundation of rare disease review.
- Guidance review and revision: A systematic reassessment could yield new or revised guidance on endpoints, statistical approaches, trial design, patient engagement, external-expert consultation, and postapproval obligations.
- Alignment within CDER and CBER: FDA contemplates improving consistency across review divisions and consolidating rare disease expertise within its Center for Drug Evaluation and Research (CDER) and its Center for Biologics Evaluation and Research (CBER).
- Training plan: Training would address nonregulatory changes and implementation after revisions, helping reviewers and leadership apply the framework consistently.
These deliverables signal potentially ambitious plans on behalf of FDA to tackle challenging regulatory issues that typically require significant personnel engagement and agency resources to complete. Recent reductions in FDA headcount may limit the breadth, scope, and speed with which FDA can deliver.
Public Meeting Takeaways and Sponsor Engagement
At the October 28 public meeting, held with the Reagan-Udall Foundation for the FDA on these issues, agency leaders emphasized transformational rather than incremental change, with one panelist calling for a “quantum leap.” The meeting focused on establishing disease- and product-specific development expectations early, rather than relying on regulatory flexibility later.
FDA invited stakeholders to describe their ideal rare disease frameworks, paired with detailed solutions. Drawing on that discussion, sponsors and other stakeholders considering providing FDA feedback on these issues could focus their comments on the following areas:
- Evidence expectations: Identify where conventional trial designs are infeasible and propose criteria for evaluating alternatives, including prespecified analyses, source verification, and safeguards to address bias and uncertainty.
- Consistency and predictability: Recommend procedures for documenting key advice, maintaining alignment at development milestones, explaining changes in expectations, and addressing conflicting feedback.
- Patient and expert input: Propose when patient and expert input should inform endpoints, study design, and benefit-risk assessment, and how its influence should be considered by regulators while addressing confidentiality and conflicts of interest.
- Manufacturing expectations: Provide real-world experiences with CMC obstacles in rare disease development programs and alternative expectations for rare disease programs.
Across these areas, sponsors should identify the appropriate implementation mechanism—guidance, regulatory amendments, internal procedures, or training—and address how changes should apply to ongoing and future programs.
Given current FDA resource constraints, stakeholders and commenters may wish to consider how necessary regulatory change can be achieved with fewer policy development or implementation resources, whether through strategic and targeted changes or through providing specific, targeted objectives and methods for FDA to consider and implement.
Submitting Written Comments and Further Engagement
Comments are due December 11, 2026, under Docket No. FDA-2026-N-12214. Electronic comments will be posted publicly; submissions containing confidential information must follow the separate paper-submission procedures.
FDA also plans further opportunities to provide input, including requests for information and sector-specific roundtables. Separately, the 2026 Strategic Agenda calls for continued public Rare Disease Innovation, Science, and Exploration (RISE) workshops in 2026 and beyond, with opportunities to propose workshop topics.
Looking Ahead
The Framework Initiative’s significance will depend on whether it converts broad policy commitments into usable development advice and consistently applied review practices. There is an immediate opportunity for sponsors and other stakeholders to help shape those practices by sharing their experience and expertise through written comments and ongoing participation in the initiative.
We will continue to monitor these developments. For questions about the Framework Initiative, opportunities to provide input, or potential implications for your development programs, please contact the authors of this blog post or your regular Morgan Lewis contacts.